We reported previously that the loss of expression of estrogen receptor (ER)-b during the development of prostate cancer (PCa) is associated with methylation of a CpG island located in the 5 0 -flanking sequence of the 0N promoter. Three methylation hotspots, referred to as centers 1, 2 and 3, were identified in the CpG island. In this study, we demonstrated that a 581-bp region with these three centers within it is sufficient for the promoter activity in PCa cells. Deletion analyses indicated that center 1 (16 bp), with a putative activator protein-2 (AP-2) binding site, is essential for gene transactivation. Chromatin immunoprecipitation assays showed that AP-2a occupies a short sequence containing center 1. Forced expression of AP-2a or -2c, but not -2b, increased activity of the ERb 0N promoter and the accumulation of mRNA. Conversely, siRNA-mediated AP-2a and -2c knockdown reduced levels of ERb transcript and promoter activity. Quantitative reverse transcription-PCR showed that AP-2a and -2c are the predominant transcripts expressed in PCa cells, and levels of ERb transcript correlate with levels of these AP-2 transcripts among different PCa cell lines. These results provide the first evidence that ERb is an AP-2-regulated gene. They also support the hypothesis that certain cis-acting elements are methylation hotspots susceptible to epigenetic modifications during cancer progression.
Introduction
Estrogens, together with androgens, regulate normal development and differentiation of the prostate (Ho et al., 2006a; Nieto et al., 2007) and play key roles in the pathogenesis of benign and malignant prostate diseases. Developmental perturbations of estrogen homeostasis increase the risk of prostate carcinogenesis (Ho et al., 2006b) . The beneficial actions of phytoestrogens in ameliorating symptoms of benign prostatic hyperplasia and in chemoprevention of prostate cancer (PCa) are well documented (Comhaire and Mahmoud, 2004) . Recently, parenteral administration of estrogen has gained popularity as a cost-effective treatment of PCa (Ockrim et al., 2006) .
The actions of estrogens have long been believed to be mediated by the classical estrogen receptor (ER), now referred to as ERa. This receptor serves as a transcription factor (TF) by binding to estrogenresponsive elements (EREs), which are found in promoter regions of target genes or in recently discovered distant cis-regulatory sequences (Carroll et al., 2006) . In 1996, a second ER, named ERb, was identified (Kuiper et al., 1996) . The two ERs have highly homologous DNA-binding domains but significantly different N-terminus and ligand-binding domains. ERb is believed to regulate a set of physiological functions different from those regulated by ERa (Imamov et al., 2005) .
In the human prostate, ERb is the principal ER subtype in epithelial cells, whereas both ERa and -b are expressed in the stroma (Horvath et al., 2001; Leav et al., 2001) . The expression of ERb is frequently and markedly reduced as normal epithelial cells undergo neoplastic transformation and as cancers progress to a higher grade (Horvath et al., 2001; Leav et al., 2001) , thus suggesting that ERb protects against uncontrolled cell proliferation in normal prostatic epithelium and might serve as a tumor suppressor during the development of PCa (Signoretti and Loda, 2001) . Paradoxically, patients with high levels of ERb in their primary PCas are more likely to develop recurrent diseases (Horvath et al., 2001) . Furthermore, ERb was found to be strongly expressed in bone and lymph node PCa metastases (Leav et al., 2001; Lai et al., 2004) . These findings suggest that ERb may have functions in addition to antiproliferation, such as promotion of PCa cell invasion and/or survival of these cells at distant sites. Thus, ERb may play multiple and critical roles during the course of PCa development and progression.
No information is available about how ERb is regulated in PCa cells except for our recent study suggesting that changes of ERb expression during prostate carcinogenesis in vivo could be regulated by DNA methylation (Zhu et al., 2004) . In this study, we identified one composite CpG island (CGI) spanning the proximal promoter and the untranslated 0N exon of the ERb gene (Figure 1 ). Bisulfite sequencing analyses of cellular DNA obtained from microdissected foci of normal epithelia and from premalignant, malignant and metastatic lesions in prostatectomy specimens revealed that the expression of ERb in vivo correlated inversely with the extent of methylation in the CGI. Three CpG clusters or 'hotspots' with the greatest susceptibility to changes in methylation within the CGI were identified. The proximal cluster or center 1 is located in the promoter region. Centers 2 and 3 are located in the untranslated 0N exon. Transfection of methylated oligonucleotides corresponding to the sequences in the hotspots induced site-specific in cellulo methylation in PC-3 cells. Only methylation of CpGs in center 1, but not in centers 2 and 3, was associated with reduced accumulation of ERb mRNA. These findings support the postulate that center 1 harbors a key regulatory sequence(s), whose accessibility by its cognate TF is impeded by DNA methylation of this region (Baylin, 2005) .
Here, we identified a noncanonical activator protein-2 (AP-2) binding site within center 1 of the ERb 0N promoter and demonstrated that it plays a crucial role in regulating ERb transcription in PCa cells. ERb is thus a newly identified transcriptional target of AP-2 in PCa cells.
Results

Identification of ERb 0N promoter as the predominant promoter used in PCa cells
Alternative usage of promoters in the 5 0 -flanking region of non-coding exons (0N or 0K) and a coding exon M resulted in two types of full-length human ERb transcripts spliced with exon 0N or 0K (Hirata et al., 2001 ) and a truncated transcript spliced with exon M, respectively (Shoda et al., 2002 ). An B2 kb 5 0 -flanking region of each promoter was cloned and evaluated by luciferase reporter assay using PC-3 cells (Figure 2a) . Of all promoters studied, only the 0N promoter exhibited significantly higher (Po0.0001) activity suggesting that the 0N promoter is the principal promoter used by PC-3 cells as well as in other PCa cells (data not shown).
Importance of the 581 bp 5
0 -flanking sequence to ERb transactivation in PCa cells Further analyses of 2157 bp (À1767/390) 0N promoter revealed that the 581 bp (À191/390) of the promoter, which contains the entire ERb 0N CGI, including all three methylation hotspots (centers 1-3; Figure 1 ), constitutes over 90% of the 2 kb promoter activity (Figure 2b ). These data indicate that the 581 bp sequence of promoter 0N (named as 0N-Luc) contains most of the essential regulatory elements of the 0N promoter. 
ChIP
Center 1 is crucial for ERb expression in PCa cells
The relative position of the 46 CpG sites in the three methylation centers identified in our previous study (Zhu et al., 2004) are shown in Figure 1 . We used the 0N-Luc (581 bp) as a template and performed serial-and center-specific deletions to characterize the role of the sequences in these methylation hotspots of the 0N promoter.
We generated six serial deletion mutants (DelA to DelF) as marked in Figures 1b and 3a (left panel) . The promoter activity of DelA, which is a construct with 76 bp (À191/À116), including 16-bp center 1 (À133/ À118), removed from the 5 0 -end of the 0N-Luc, was 61% lower than that of 0N-Luc ( Figure 3a , right panel). An additional deletion of a 172 bp from 5 0 -end that includes a predicted TATA box, the transcriptional start site ( Figure 1 ) and a small portion of center 2 (DelB) caused another 24% decrease in promoter activity. Further deletions (DelC to DelF) that either completely or partially removed center 2 and/or center 3 did not result in additional losses of promoter activity, indicating that the 76 bp which includes center 1 may contain the principal regulatory region for ERb transcription.
We next performed center-specific deletions (highlighted in Figure 1b ) to study the contribution of each center in terms of promoter activity. Consistent to the serial deletion experiment, only deletion of center 1, but not centers 2 or 3, resulted in a 59% decrease in promoter activity as compared with that of 0N-Luc ( Figure 3b ). Collectively, our data strongly support the hypothesis that the 16-bp short sequence corresponding to center 1 plays a crucial role in ERb gene regulation.
Center 1 harbors an AP-2 cis-regulatory element that upregulates ERb expression By using MatInspector, we uncovered a putative noncanonical AP-2 binding site corresponding to CpG5-8 in center 1 in the 0N promoter (Figure 1b; underscored) . We then performed the following experiments to investigate the possible role of AP-2 in regulation of ERb expression.
Forced expression of AP-2a or -2g, but not AP-2b, induced significant transactivation of the 0N-Luc promoter ( Figure 4a ). Chromatin immunoprecipitation (ChIP) assay revealed that only AP-2a but not AP-2b or -2g can bind to a 172 bp sequence (À191/21) harboring center 1 in PC-3 cells (Figure 4b ). AP-2a and -2g transcripts were readily detectable by real-time reverse transcription (RT)-PCR, whereas expression of AP-2b was low to absent in PCa cells (Figure 4c ). The overall expression of AP-2 transcripts, in descending order, were PC-3, DU145 and LNCaP. Coincidently, ERb transcripts accumulation in these three cell lines paralleled those of AP-2 transcripts (Figure 4d ). These data indicate that AP-2 may regulate ERb expression via the noncanonical AP-2 binding site in center 1. ERb is a transcriptional target of AP-2 X Zhang et al Forced expression or siRNA-mediated knockdown of AP-2 induced concordant changes in ERb expression AP-2a and -2g expression plasmids were transfected with or without a dominant negative AP-2D plasmid into PC-3 cells, in which its ERb 0N promoter is unmethylated (Zhu et al., 2004) , and thus interaction between AP-2 and its cis-regulatory element will not be hindered by methylation. Real-time RT-PCR demonstrated that forced expression of AP-2a or -2g, but not AP-2b (data not shown), in PC-3 cells induced significant increases (135-185%) in ERb transcripts as compared with the empty vector control (Figure 5a ). Such effects can be reversed by co-transfecting AP-2D into the same system, demonstrating the specificity of AP-2. Conversely, siRNA-mediated double knockdown (Figure 5b ) of AP-2a and -2g transcripts in PC-3 cells resulted in 76-79% reduction of AP-2 transcripts and 81% decrease in ERb mRNA. Further investigation using DU145 cell, which expresses lower endogenous AP-2, revealed that AP-2a and -2g, but not AP-2b (data not shown), can upregulate 0N promoter activity in a dose-dependent manner, and its activity can be suppressed by AP-2D co-expression (Figure 5c ).
Discussion
Androgens and androgen receptor signaling are critical for the survival of advanced PCa cells (Nieto et al., 2007) . Yet, almost all currently available treatments targeting androgen receptor fail to fully stop PCa progression. Thus, investigations of other signaling pathways, including those mediated by ERb, a predominant nuclear receptor in advanced PCa (Leav et al., 2001; Lai et al., 2004) , are likely to provide additional clinical benefits in the future.
The malignant phenotype emerges as genetic and epigenetic mechanisms work hand in hand to alter the expression of a conglomerate of oncogenes and tumor-suppressor genes (Garinis et al., 2002) . Among these is ERb, whose role in prostate carcinogenesis remains incompletely understood. In normal prostatic epithelial cells, ERb is thought to curb unscheduled cell proliferation (Leav et al., 2001) . The receptor has been proposed to function as a tumor suppressor, since its expression is lost during the development and progression of cancer in the prostate (Horvath et al., 2001; Leav et al., 2001) . However, the re-appearance of ERb in lymph node and bone metastases fuels the argument that it might facilitate the escape to or survival of PCa cells to distant metastatic sites (Signoretti and Loda, 2001 ). We observed recently distinct changes in methylation status in a CGI of the ERb 0N promoter flanking region that were associated with loss and gain of ERb expression related to cancer progression in clinical prostate specimens and proposed that cytosine methylation is a mechanism of gene regulation (Zhu et al., 2004) . High-resolution mapping of methylated cytosines in the 5 0 -flanking region of the ERb gene uncovered three methylation hotspots (centers 1-3) located separately in the proximal promoter region and the untranslated exon 0N (Zhu et al., 2004) . In the present study, guided by the relative position of these centers within the promoter region, we designed serial and site-specific deletion strategies to definitively demonstrate that the 16-bp center 1 of the ERb 0N promoter is crucial for the gene regulation. Once center 1 was deleted, the promoter activity decreased drastically by B60%. This finding led us to postulate that a TF binding site, which is sensitive to methylation-inactivation, might reside in center 1. In silico analyses revealed a putative AP-2 binding site (5 0 -CGCC CGA CGC CGC-3 0 , minus strand with the motif underscored) in this region. Interestingly, further deletion close to center 2 engendered only an additional 24% loss of promoter activity, which could be due to the deletion of a predicted TATA box immediately upstream of the transcriptional start site. Further 3 0 -deletions or deletion of center 3 had little impact on promoter activity, indicating that the exon 0N is not a major regulatory region for ERb transcription. On the basis of these findings, we focused a significant part of this study on demonstrating the regulatory function of this putative AP-2 site. An AP-2 site most commonly comprises at least one GCC motif (Mohibullah et al., 1999) . Of the known AP-2 sites, 80% contain two such motifs (5 0 -GCCN 3-6 GGC-3 0 ), arranged in an opposite orientation, flanking a central variable sequence of three to six nucleotides. Our predicted AP-2 motif in the ERb 0N promoter has one GCC and a 3N-spacer that aligns to center 1. Using ChIP assays, we demonstrated occupancy of a 173-bp sequence harboring this site by AP-2a protein. Real-time RT-PCR further demonstrated that AP-2a transcript is the predominant transcript found at high levels in PC-3 cells, low levels in DU145 cells, and barely detectable levels in LNCaP cells. Levels of ERb transcripts among these three cell lines paralleled those of AP-2 transcripts. Additionally, forced expression or knockdown of AP-2a and -2g, but not AP-2b, induced concordant changes in ERb transcript accumulation and promoter activity. Collectively, these findings indicated that the ERb promoter is inducible by AP-2 and that ERb transactivation is critically dependent on the region of the promoter containing this noncanonical AP-2 site.
The AP-2s are TFs that interact with cis-regulatory elements via formation of dimers to regulate the gene expression (Hilger-Eversheim et al., 2000) . Importantly, previous studies indicated that AP-2a is a methylationsensitive cis-acting element (Hermann and Doerfler, 1991) . Five known members of AP-2 gene family have been identified (Tummala et al., 2003) , of which, AP-2a, -2b and -2g were the best characterized. Essential functions of AP-2 include regulation of cell growth, differentiation and apoptosis during development (Hilger-Eversheim et al., 2000) . Aberrant or untimely expression of these molecules possibly results in congenital defects and neoplastic transformation. However, the levels of expression of different members of the family vary among different types of cells/tissues and the ability of an AP-2 to transactivate a gene is both promoter-and tissue-specific (Hilger-Eversheim et al., 2000) . Our study showed that AP-2a and -2g are equally effective in transactivating the ERb promoter, whereas AP-2b has minimal effects. AP-2a and -2g transcripts are also the predominant transcripts in PC-3 and DU145 cells. These findings are similar to those reported for the c-erbB2 promoter (Bosher et al., 1996) and suggest that specific AP-2 proteins could be the major physiological regulators of ERb expression in prostate cells.
AP-2 family proteins are now recognized as key regulators of carcinogenesis (Pellikainen and Kosma, 2007) . Germane to this concept, AP-2 were shown to upor downregulate an increasing number of cancerassociated genes including p21WAF/CIP, transforming growth factor-a, c-Kit, HER-2/neu, MCAM/MUC18 and c-myc (Hilger-Eversheim et al., 2000), VEGF and MMP-2 (BAR-ELI, 2001), and KAI1 (Marreiros et al., 2005) and KiSS-1 (Mitchell et al., 2006) . The combined actions of altered expression of these genes by AP-2-family proteins suggest that these molecules participate in the blockade of cell-cycle progression, stimulation of apoptosis, inhibition of cell invasion and angiogenesis, and promotion of differentiation.
Apropos to prostate carcinogenesis, expression of AP2a was found in normal prostate epithelium but not in 30 PCa specimens of different Gleason scores (Ruiz et al., 2001) . Somewhat similar to AP-2 expression, ERb expression was no longer detectable in over 50 clinical specimens (Leav et al., 2001) . Since AP-2 was found to be an upstream regulator of ERb transcription in this study, it is logical for us to propose that the initial cause for ERb downregulation seen during PCa progression is diminished AP-2-induced transactivation. However, we also learned from our previous study that progressive hypermethylation of the ERb 0N CGI was associated with the loss of ERb in high-grade cancers (Zhu et al., 2004) . We had concluded that DNA methylation caused the ERb silencing. To reconcile these two scenarios, we now propose that the loss of AP-2 expression is the initial cause of diminished ERb expression, which is accompanied by a reduction in the frequency of occupancy of the AP-2 site in the ERb 0N promoter by AP-2 proteins, therefore allowing DNA methyltransferases to catalyse cytosine methylation within this site, which then triggers a complex cascade of chromatinremodeling events that lead to long-term silencing of the gene (Baylin, 2005) . Nevertheless, future work is needed to provide experimental evidence in support of this theory.
In summary, ERb is now a newly identified downstream target of AP-2. CpG center 1 plays a critical role in ERb gene regulation in the prostate. AP-2 enhances ERb expression via direct interaction with a cisregulatory element located in center 1 of the ERb 0N promoter. These findings suggest cis-regulatory elements that have inherent functions in gene regulation are 'hotspots' for epigenetic modification during cancer progression.
Materials and methods
Construction of the ERb 0N, -0K and -M promoter-reporters
With the transcription initiation site designated as þ 1 in exon 0N (1-329), 0K (1-199) or exon M (1-141), the 2157 bp (À1767 to 390) promoter 0N, the 2171 bp (À1957 to À214) promoter 0K, and the 1936 bp (À1819 to 117) promoter M were amplified. PCRs were carried out by Platinum Taq high fidelity (Invitrogen, Carlsbad, CA, USA). Primers used for the first round PCR (F1 and R1) and nested PCR (F2 and R2) were shown in Table 1 . The resulting products were sequenced and cloned into pGL3b vector (Promega, Madison, WI, USA) for promoter analyses (Figure 2a) .
Preparation of various ERb 0N promoter-reporter constructs via serial and site-specific deletions A shorter version of 581 bp (Figure 1) 0N promoter was subcloned into pGL3b and named as 0N-Luc. Primers (F3 and R3) with compatible restriction sites (underlined in Table 1) were used in PCR. CpG center-specific deletions were performed by PCR with primers D1F/R, D2F/R and D3F/R (Table 1) , respectively, using the circular plasmid as the template. After self-ligation, the cloned mutants ( Figure 3b ) were sequenced and re-cloned into pGL3b.
Cell culture and transfections
Human PCa cell lines PC-3, DU145 and LNCaP were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in ATCC standard condition.
With Lipofectamine and Plus reagents (Invitrogen), cells were plated at 6 Â 10 4 cells/well in 24-well plates for transfection. In each well, 0.16 mg promoter-reporter, together with 0.04 mg of CMV-lacZ, were co-transfected. The cells were cultured for B48 h before analyses. The transfection efficiency for PC-3, DU145 and LNCaP is B20, 15 and 5%, respectively.
Human AP-2a, -2b, -2g, and -2D (an AP-2a-dominant negative) expression plasmids were a generous gift from Dr Frederick E Domann (Zhu et al., 2001) . The effect of AP-2 on 0N-Luc activity in PC-3 cells was analysed by cotransfecting 0.08 mg of AP-2 plasmid, 0.08 mg 0N-Luc, together with 0.04 mg of CMV-lacZ in each well of 24-well plates. Similar experiments were performed using DU145 cells. pGEM-T vector (Promega) was used to make up the same amount of DNA during transfection. Promoter activity was performed with Luciferase assay kit (Promega) by using Wallac 1420 Vector2 Multilabel counter (PerkinElmer, Boston, MA, USA), and normalized by b-galactosidase activity (b-galactosidase enzyme assay system; Promega).
The effect of AP-2 on ERb mRNA expression was studied by transfecting 0.4 mg of AP-2a, -2b or -2g, together with 0.4 mg of AP-2D or pGEM-T into 1 Â 10 6 PC-3 cells/well in 6-well plates via Nucleofector Kit V from Amaxa (Gaithersburg, MD, USA). The transfection efficiency is B60%. Cells were cultured for 24 h before analyses.
AP-2 ChIP assay
ChIP assays were performed with the EZ ChIP kit from Upstate (Lake Placid, NY, USA). DNA-protein complexes were sonicated with the Branson Sonifier 250 (Branson Ultrasonics, Danbury, CT, USA); a total of 2.5 mg AP-2 antibody purchased from Santa Cruz Technology (Santa Cruz, CA, USA), specific to AP-2a (sc-12726), -2b (sc-8976) or -2g (sc-8977) was used; with primers ChIP-F and ChIP-R (Figure 1b and Table 1 ), PCR was performed by using Platinum Taq (Invitrogen) in the presence of 5% dimethylsulfoxide under an initial denaturation at 941C for 1 min, followed by 33 cycles of 941C for 30 s, 551C for 30 s and 721C for 15 s.
siRNA-mediated AP-2 knockdown PC-3 (6 Â 10 4 cells/well) was seeded in the 6-well plates on day 0. On day 1, transfection was performed with 5 ml of Lipofectamine 2000 (Invitrogen) and 3.75 ml each of 20 mM AP-2a (L-006348-00) and AP-2g siRNA (L-005238-00) from Dharmacon (Lafayette, CO, USA). Non-targeting siRNA Pool (D-001210-01-05) was used as the control. On day 3, the cells were re-plated at same density and the second round of transfection was performed on day 4. Cells were collected on day 7 for RNA extraction.
Real-time RT-PCR for detecting ERb and AP-2 mRNA levels RNA was extracted with Trizol reagent (Invitrogen). Reverse transcription was performed with the SuperScript III kit (Invitrogen). mRNA was analysed using Power SYBR Green and 7500 Fast Real-Time system (ABI, Foster City, CA, USA) except for 18S rRNA, in which 1 ml of 1:2.5 Â 10 5 diluted cDNA was used in a 20-ml reaction. ERb transcripts were detected using the primers from previous report (Lau et al., 2000) . Primers for AP-2a, -2b, -2g, GAPDH and 18S were shown in Table 1 . The PCR condition was 501C for 2 min, 951C for 10 min, followed by 50 cycles of 951C for 15 s and 601C for 75 s. The 2
ÀDDCt method (Livak and Schmittgen, 2001 ) was used to calculate the relative expression level of the transcripts. TTC TGC CTG TTG GCT TAT GGT TGA  R1  TCT TCC CAG GCC CTC AAA GTT CA  F2  CAT GAC GGT TTC CAT TTC CAG AGA  R2  CAC CGC AGG ATT TCA AAC AAA  ATG A  F3  agg taC CAC TAT CCT TGT GGG TG  R3  gta agc ttC ACC GCA GGA TTT CAA ACA  AAA TG  D1F  TTC CTG AGA CCG TCG GGC TCC  D1R  TGA ERb is a transcriptional target of AP-2 X Zhang et al
Bioinformatic analysis
The GenBank accession no. for 0N promoter sequence is NT_026437. 
Statistical analyses
To compare multiple groups, one-way analysis of variance, followed by Tukey's HSD post hoc test, was used to determine the statistical significance. To compare two groups, a twotailed, unpaired t-test was performed.
